Related Experiment Video
Updated: Mar 10, 2026
Single-cell RNA Sequencing and Analysis of Human Pancreatic Islets
Published on: July 18, 2019
Gene expression signature: a powerful approach for drug discovery in diabetes
Smithamol Sithara1, Tamsyn M Crowley2, Ken Walder1
1Metabolic Research UnitSchool of Medicine, Deakin University, Geelong, Australia.
Abstract:
Type 2 diabetes (T2D) is increasing in prevalence at an alarming rate around the world. Much effort has gone into the discovery and design of antidiabetic drugs; however, those already available are unable to combat the underlying causes of the disease and instead only moderate the symptoms. The reason for this is that T2D is a complex disease, and attempts to target one biological pathway are insufficient to combat the full extent of the disease. Additionally, the underlying pathophysiology of this disease is yet to be fully elucidated making it difficult to design drugs that target the mechanisms involved. Therefore, the approach of designing new drugs aimed at a specific molecular target is not optimal and a more expansive, unbiased approach is required. In this review, we will look at the current state of diabetes treatments and how these target the disease symptoms but are unable to combat the underlying causes. We will also review how the technique of gene expression signatures (GESs) has been used successfully for other complex diseases and how this may be applied as a powerful tool for the discovery of new drugs for T2D.
Insights
Type 2 diabetes (T2D) treatments only manage symptoms, not causes. Gene expression signatures (GESs) offer a promising, unbiased approach for discovering new T2D drugs by targeting the disease's complexity.
Area of Science:
- Biomedical research
- Pharmacology
- Genomics
Background:
- Type 2 diabetes (T2D) prevalence is rising globally.
- Current T2D drugs manage symptoms but do not address underlying causes.
- T2D is a complex disease with incompletely understood pathophysiology, hindering targeted drug design.
Purpose of the Study:
- To review current T2D treatments and their limitations.
- To explore the potential of gene expression signatures (GESs) for T2D drug discovery.
- To advocate for a more expansive, unbiased approach to T2D therapeutics.
Main Methods:
- Literature review of existing antidiabetic drug discovery approaches.
- Analysis of the application of gene expression signatures (GESs) in complex diseases.
- Discussion of the suitability of GESs for T2D research.
Main Results:
- Existing T2D treatments primarily offer symptomatic relief.
- Targeting single pathways is insufficient for complex diseases like T2D.
- Gene expression signatures (GESs) have proven effective in other complex diseases.
Conclusions:
- A paradigm shift from single-target drug design to holistic approaches is needed for T2D.
- Gene expression signatures (GESs) represent a powerful, unbiased tool for identifying novel T2D therapeutic targets.
- Applying GESs could accelerate the development of more effective treatments for Type 2 diabetes.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
01:58Cell Specific Gene Expression
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...